Soluble CD14: a new Prognostic Factor in Patients with Chronic Lymphocytic Leukaemia

Abstract

Background: CLL is presently an incurable disease characterized by progressive accumulation of mature lymphocyte in bone marrow and peripheral blood cause heterogeneous clinical course ranging from indolent to aggressive disease. So, many efforts focus on finding reliable indicators that can help to predict the outcome or explain clinical variability. Cluster of differentiation 14 (CD 14) has been emerged as one of these indicators, But it needs thorough assessment for its prognostic capacity in CLL. This gave us the ardor to carry out this study. Objective: the current study was conducted to assess the level of CD14 in serum of CLL patients and evaluate its relation to clinical stage and other prognostic parameters and study its probable prognostic role in CLL patients. Patients and methods: forty five Iraqi newly diagnosed B-CLL patient and forty five age and sex matched healthy control were included in this study for evaluation of serum CD14 by Enzyme Linked Immunosorbent Assay'' ELISA''. Results: The mean serum CD14 level was found to be significantly higher in patients' serum than control and it was higher among patients with advanced stage (Binet stage C and high risk (III-IV) Modified Rai Stage). There had been a significant relation between sCD14 level and patients with organomegaly and those with specific complications. There were no mean differences between CD14 level and patient's age or gender and there was no significant relation to hematological parameters. Conclusions: sCD14 level was significantly higher in CLL patients than control group.